Protein clues could spot rare disease years early
NCT ID NCT03431896
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study followed 37 people with a genetic risk for hereditary ATTR amyloidosis over five years. Researchers measured levels of misfolded proteins in the blood to see if they could detect the earliest signs of the disease. The goal is to develop a way to catch the condition before symptoms appear, potentially allowing for earlier treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a blood test that catches ATTR amyloidosis earlier, allowing for timely treatment.
- What could go wrong
- This is a small observational study (37 people) that only measures a biomarker, not a treatment. The protein changes may not reliably predict disease onset in all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AL AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A hidden warning in your wrist? surgery may reveal heart risk
- Can a daily pill keep a rare heart disease in check for the long haul?
- Can a Dual-Targeting antibody stop amyloid buildup in its tracks?
- Can a radioactive peptide spot hidden amyloid in the heart?
- Real-world data on multiple myeloma immunotherapies could reshape monitoring and improve survival
- Heart drug acoramidis tested for Long-Term cardiac repair in rare amyloidosis